Total Funding
44
93
Total FundingPost-IPO Equity raised
Growth Score
-23 pts
Heat Score
6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
19793
Immutep is a globally active leader in the development of personalized immunocellular therapeutic products for the treatment of cancer.
- Deanne Miller: Chief Operating OfficerPast Role: Immutep, General Counsel and Company Secretary
- Stephan Winckels: Chief Medical OfficerPast Role: Cleara Biotech, Senior Medical Director
About the Company
Immutep is a globally active leader in the development of personalized immunocellular therapeutic products for the treatment of cancer. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep's lead product is CVac™, an
autologous dendritic cell-based product currently in clinical trials for ovarian cancer patients in remission, and soon starting a pilot trial for resected pancreatic cancer. Immutep is listed on the Australian stock exchange, on the NASDAQ in the US and in Germany on the Deutsche Börse in an entry standard.
